Brief: Nektar Therapeutics Q3 EPS USD -1.87
06/11/2025 21:15
Nov 06 (Reuters) - Nektar Therapeutics Q3 income from operations USD -31.672 million. Q3 product sales USD 11.79 million Q3 net income USD -35.522 million
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says